CoChat

Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances

Open access

The DOI matches its Crossref record; 555 of the 555 references it cites were found in a registry or an index; 131 of the 460 sources its claims cite were checked for support.

Abstract

In the context of global ageing, the prevalence of neurodegenerative diseases and dementia, such as Alzheimer’s disease (AD), is increasing. However, the current symptomatic and disease-modifying therapies have achieved limited benefits for neurodegenerative diseases in clinical settings. Halting the progress of neurodegeneration and cognitive decline or even improving impaired cognition and function are the clinically meaningful goals of treatments for neurodegenerative diseases. Ageing is the primary risk factor for neurodegenerative diseases and their associated comorbidities, such as vascular pathologies, in elderly individuals. Thus, we aim to elucidate the role of ageing in neurodegenerative diseases from the perspective of a complex system, in which the brain is the core and peripheral organs and tissues form a holistic network to support brain functions. During ageing, the progressive deterioration of the structure and function of the entire body hampers its active and adaptive responses to various stimuli, thereby rendering individuals more vulnerable to neurodegenerative diseases. Consequently, we propose that the prevention and treatment of neurodegenerative diseases should be grounded in holistic antiageing and rejuvenation means complemented by interventions targeting disease-specific pathogenic events. This integrated approach is a promising strategy to effectively prevent, pause or slow down the progression of neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

This review argues that because ageing is the primary risk factor for neurodegenerative diseases, treatment should be grounded in holistic antiageing and rejuvenation strategies across molecular, cellular, systemic and individual levels, complemented by interventions targeting disease-specific pathogenic events. It synthesizes preclinical and clinical evidence for such an integrated approach to preventing, pausing or slowing neurodegeneration.

Key findings

  • Ageing is presented as an "accelerator" of neurodegeneration: AD prevalence rises from 5% at ages 65–74 to 13.1% at 75–84 and 33.2% at 85+ (US, 2022); PD prevalence rises from 41 per 100,000 at ages 40–49 to 1,903 per 100,000 at 80+; ALS prevalence is 0.2 per 100,000 at ages 18–39 versus 17.2 per 100,000 at 70–79.
  • Comorbidities are the rule rather than the exception: in the ROS/MAP cohort, ~97% of persons with probable AD had other neurodegenerative or vascular comorbidities, and >86% of cognitively unimpaired older persons had vascular, AD or other degenerative comorbidities.
  • The authors propose a complex adaptive systems (CAS) framework in which neurodegeneration arises from emergent homeostatic imbalance across molecular, cellular, organ and organismal scales, rather than from a single molecule or cell.
  • Antiageing interventions are catalogued across levels: molecular (e.g., GDF11, klotho, metformin lowering epigenetic age by up to 6.1 years in the frontal lobe of monkeys; rapamycin/acarbose/phenylbutyrate cocktails), cellular (senolytics extending lifespan up to 35% in pre-ageing mice; young plasma extracellular vesicles increasing median lifespan 12.4%), systemic (young blood, bone marrow transplantation increasing maximum lifespan 30%, FMT, anti-inflammation such as IL-11 neutralization extending average mouse lifespan 24.9%), and individual (caloric restriction, exercise, sleep/diet; a multimodal diet-exercise-sleep intervention reversed epigenetic age by 3.2 years).
  • Clinical trials reviewed include effective results for allopregnanolone, isoflavones, benfotiamine, fish oil/lipoic acid, and plasma exchange, while intranasal insulin, naproxen/celecoxib and nilotinib were ineffective; senolytics showed phase 1 safety in AD.

Methods

  • Narrative review (no systematic search or meta-analytic protocol described) synthesizing epidemiological, mechanistic, preclinical and clinical literature on ageing and neurodegenerative diseases (AD, PD, ALS, FTLD, HD).
  • Evidence drawn from population/epidemiological datasets (WHO, CDC, ROS/MAP, UK Biobank, CALERIE, REACT), animal and cell models, and a tabulated set of clinical trials (Table 2) with identifiers, phases and reported results.
  • Organizes evidence by mechanistic level (molecular, cellular, tissue/organ, circuit, functional), by body–brain axes (heart, liver, gut, kidney, lung, muscle, bone, blood, immune, endocrine), and by intervention level (molecular, cellular, systemic, individual).

Limitations

  • Stated by the paper: most studies are conducted in artificially induced animal models (e.g., APP/PS1 mice) that do not reflect sporadic disease, since familial AD accounts for less than 5% of cases; such models may underestimate peripheral and brain ageing contributions.
  • Stated by the paper: mouse, Drosophila and nematode lifespans are inadequate for modelling gradual human ageing, so antiageing therapies should be validated in longer-lived species (non-human primates, naked mole rats).
  • Stated by the paper: the magnitude and duration of antiageing effects require long-term follow-up; individual heterogeneity (age, personality, comorbidities, lifestyle, education) is poorly understood; and side effects/adverse reactions are often downplayed.
  • Evident from the text: as a narrative review without a systematic search strategy, selection of cited evidence may be subject to the authors' framing, and several cited clinical trials are ongoing with results not yet reported (blank entries in Table 2).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-025-02145-7

Cites

555 of 555 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Prevalence or incidence of neurodegenerative diseases by age. Epidemiological evidence indicates that ageing is an accelerator of neurodegenerative diseases. The prevalence of AD was based on the data of 2000 in the United States and Europe. The global prevalence of PD was based on the data from 1985 to 2010. The prevalence of ALS was based on the data of 2016 in the United States. The incidence of FTLD was based on the data of 2021 in Europe. AD Alzheimer’s disease, PD Parkinson’s disease, ALS Amyotrophic lateral sclerosis, FTLD Frontotemporal lobar degeneration
Fig. 1 Prevalence or incidence of neurodegenerative diseases by age. Epidemiological evidence indicates that ageing is an accelerator of neurodegenerative diseases. The prevalence of AD was based on the data of 2000 in the United States and Europe. The global prevalence of PD was based on the data from 1985 to 2010. The prevalence of ALS was based on the data of 2016 in the United States. The incidence of FTLD was based on the data of 2021 in Europe. AD Alzheimer’s disease, PD Parkinson’s disease, ALS Amyotrophic lateral sclerosis, FTLD Frontotemporal lobar degenerationCC BY · PubMed Central
Fig. 2 Milestone events in the history of antiageing research. This figure enumerates key events in the field of antiageing research and pivotal advancements in unitizing antiageing strategies to intervene neurodegenerative diseases from the 1930s onwards. NIA National Institute on Aging, ITP Intervention Testing Program, SIR4 sirtuin 4, NAD+ nicotinamide adenine dinucleotide, TOR target of rapamycin, C. elegans Caenorhabditis elegans, AD Alzheimer’s disease, PD Parkinson’s disease
Fig. 2 Milestone events in the history of antiageing research. This figure enumerates key events in the field of antiageing research and pivotal advancements in unitizing antiageing strategies to intervene neurodegenerative diseases from the 1930s onwards. NIA National Institute on Aging, ITP Intervention Testing Program, SIR4 sirtuin 4, NAD+ nicotinamide adenine dinucleotide, TOR target of rapamycin, C. elegans Caenorhabditis elegans, AD Alzheimer’s disease, PD Parkinson’s diseaseCC BY · PubMed Central
Fig. 3 Overview of integrated systems involved in AD pathogenesis. AD was initially proposed to obey the Aβ cascade hypothesis, with Aβ as its core. Dysregulation of Aβ production and clearance leads to its accumulation, which further induces downstream oxidative stress, NFT formation, neuronal and synaptic degeneration, and ultimately dementia. Here, we propose viewing AD from the perspective of integrated systems. When intense stimulation exceeds the body’s resistance or when the resilience is insufficient to recover from the stimulus-induced disruption, homoeostatic imbalances result, as evidenced by Aβ and tau accumulation, synaptic/neuronal degeneration, and dementia. Genes, the environment and lifestyle are involved at every level. AD Alzheimer’s disease, APP amyloid precursor protein, Aβ amyloid-β, PS presenilin, NFTs neurofibrillary tangles. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe Illustrator
Fig. 3 Overview of integrated systems involved in AD pathogenesis. AD was initially proposed to obey the Aβ cascade hypothesis, with Aβ as its core. Dysregulation of Aβ production and clearance leads to its accumulation, which further induces downstream oxidative stress, NFT formation, neuronal and synaptic degeneration, and ultimately dementia. Here, we propose viewing AD from the perspective of integrated systems. When intense stimulation exceeds the body’s resistance or when the resilience is insufficient to recover from the stimulus-induced disruption, homoeostatic imbalances result, as evidenced by Aβ and tau accumulation, synaptic/neuronal degeneration, and dementia. Genes, the environment and lifestyle are involved at every level. AD Alzheimer’s disease, APP amyloid precursor protein, Aβ amyloid-β, PS presenilin, NFTs neurofibrillary tangles. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe IllustratorCC BY · PubMed Central
Fig. 4 Schematic diagram of the decline in brain adaptation during ageing and neurodegenerative diseases. a Young and healthy brains can actively respond to various stimuli, thus maintaining homoeostasis and normal brain function. During ageing, the compromised adaptation of the brain is insufficient to recover from stimulus-induced perturbations, resulting in a homoeostasis imbalance and the development of disease. b In the brains of neurodegenerative disease patients, pure neurodegenerative disease pathology is relatively rare and is often accompanied by other pathological changes, such as vascular damage and the aggregation of pathological proteins (e.g., TDP43 and Lewy bodies). Once these comorbidities occur, cognitive decline appears earlier, progresses more rapidly, and reaches lower levels. NDs neurodegenerative diseases, Aβ amyloid-β, BBB blood–brain barrier, NFTs neurofibrillary tangles, TDP43 transactive response DNA binding protein 43. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe Illustrator
Fig. 4 Schematic diagram of the decline in brain adaptation during ageing and neurodegenerative diseases. a Young and healthy brains can actively respond to various stimuli, thus maintaining homoeostasis and normal brain function. During ageing, the compromised adaptation of the brain is insufficient to recover from stimulus-induced perturbations, resulting in a homoeostasis imbalance and the development of disease. b In the brains of neurodegenerative disease patients, pure neurodegenerative disease pathology is relatively rare and is often accompanied by other pathological changes, such as vascular damage and the aggregation of pathological proteins (e.g., TDP43 and Lewy bodies). Once these comorbidities occur, cognitive decline appears earlier, progresses more rapidly, and reaches lower levels. NDs neurodegenerative diseases, Aβ amyloid-β, BBB blood–brain barrier, NFTs neurofibrillary tangles, TDP43 transactive response DNA binding protein 43. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe IllustratorCC BY · PubMed Central
Fig. 5 Specific mechanisms by which ageing promotes different neurodegenerative diseases. a Ageing promotes specific neurodegenerative diseases. Ageing is a holistic non-specific process that nevertheless facilitates the emergence of distinct types of neurodegenerative diseases in different individuals. Ageing is co-regulated by both environment and genetic factors (wherein the latter are also subject to environment). As well, ageing exerts an effect on the specific risk factors associated with different neurodegenerative diseases. The interplay between environmental and genetic factors co-regulates ageing, with the latter also being influenced by environmental conditions. Furthermore, ageing impacts the specific risk factors associated with different neurodegenerative diseases. These four aforementioned aspects synergistically interact with the unique mechanisms and pathways underlying neurodegenerative diseases. b Brain ageing acts on the AD pathway. During brain ageing, molecular, cellular, and tissue/systemic networks undergo profound transformations that promote specific pathways conducive to various neurodegenerative diseases. For example, AD is characterized by Aβ accumulation, which occurs alongside age-related comorbidities leading to neuronal degeneration and AD progression. In the context of brain ageing, Aβ-degrading enzymes and amyloidogenic processing of APP directly affect both Aβ production and clearance rates. Key hallmarks of ageing include oxidative stress, mitochondrial dysfunctions, genomic instability, proteasome and lysosomal dysfunctions as well as nutrient perception disorders; these factors collectively enhance Aβ deposition. Additionally, age-related reductions in microglial activity and transport systems such as the blood-brain barrier and glymphatic system impair Aβ clearance efficiency. The accumulation of Aβ triggers downstream formation of NFTs, further exacerbating hallmark features associated with ageing while concurrently diminishing neuroglial support for neurons, this combination accelerates neuronal degeneration linked to AD pathology. Moreover, neuroinflammation along with alterations in structural integrity and functional capabilities within an ageing brain contribute significantly to AD pathogenesis; peripheral organ ageing also plays a role in influencing AD progression through direct effects on Aβ dynamics as well as indirect effects on brain ageing. APP amyloid precursor protein, PS presenilin, ApoE Apolipoprotein E, TREM2 triggering receptor expressed on myeloid cells 2, SNCA synuclein alpha, LRRK2 leucine-rich repeat kinase 2, PINK1 PTEN-induced putative kinase 1, PRKN parkin RBR E3 ubiquitin protein Ligase, SOD1 superoxide dismutase 1, C9orf72 chromosome 9 open reading frame 72, FUS fused in sarcoma, TDP-43 transactive response DNA binding protein 43, MAPT microtubule associated protein tau, GRN granulin, HTT huntingtin, AD Alzheimer’s disease, PD Parkinson’s disease, ALS Amyotrophic lateral sclerosis, FTLD Frontotemporal lobar degeneration, HD Huntington’s disease, NFTs neurofibrillary tangles, Aβ amyloid-β, α-syn α-synuclein
Fig. 5 Specific mechanisms by which ageing promotes different neurodegenerative diseases. a Ageing promotes specific neurodegenerative diseases. Ageing is a holistic non-specific process that nevertheless facilitates the emergence of distinct types of neurodegenerative diseases in different individuals. Ageing is co-regulated by both environment and genetic factors (wherein the latter are also subject to environment). As well, ageing exerts an effect on the specific risk factors associated with different neurodegenerative diseases. The interplay between environmental and genetic factors co-regulates ageing, with the latter also being influenced by environmental conditions. Furthermore, ageing impacts the specific risk factors associated with different neurodegenerative diseases. These four aforementioned aspects synergistically interact with the unique mechanisms and pathways underlying neurodegenerative diseases. b Brain ageing acts on the AD pathway. During brain ageing, molecular, cellular, and tissue/systemic networks undergo profound transformations that promote specific pathways conducive to various neurodegenerative diseases. For example, AD is characterized by Aβ accumulation, which occurs alongside age-related comorbidities leading to neuronal degeneration and AD progression. In the context of brain ageing, Aβ-degrading enzymes and amyloidogenic processing of APP directly affect both Aβ production and clearance rates. Key hallmarks of ageing include oxidative stress, mitochondrial dysfunctions, genomic instability, proteasome and lysosomal dysfunctions as well as nutrient perception disorders; these factors collectively enhance Aβ deposition. Additionally, age-related reductions in microglial activity and transport systems such as the blood-brain barrier and glymphatic system impair Aβ clearance efficiency. The accumulation of Aβ triggers downstream formation of NFTs, further exacerbating hallmark features associated with ageing while concurrently diminishing neuroglial support for neurons, this combination accelerates neuronal degeneration linked to AD pathology. Moreover, neuroinflammation along with alterations in structural integrity and functional capabilities within an ageing brain contribute significantly to AD pathogenesis; peripheral organ ageing also plays a role in influencing AD progression through direct effects on Aβ dynamics as well as indirect effects on brain ageing. APP amyloid precursor protein, PS presenilin, ApoE Apolipoprotein E, TREM2 triggering receptor expressed on myeloid cells 2, SNCA synuclein alpha, LRRK2 leucine-rich repeat kinase 2, PINK1 PTEN-induced putative kinase 1, PRKN parkin RBR E3 ubiquitin protein Ligase, SOD1 superoxide dismutase 1, C9orf72 chromosome 9 open reading frame 72, FUS fused in sarcoma, TDP-43 transactive response DNA binding protein 43, MAPT microtubule associated protein tau, GRN granulin, HTT huntingtin, AD Alzheimer’s disease, PD Parkinson’s disease, ALS Amyotrophic lateral sclerosis, FTLD Frontotemporal lobar degeneration, HD Huntington’s disease, NFTs neurofibrillary tangles, Aβ amyloid-β, α-syn α-synucleinCC BY · PubMed Central
Fig. 6 The impacts of the body‒brain axis ageing on neurodegenerative diseases. The brain interacts with multiple peripheral organs, and the functions and structures of peripheral organs change with age, leading to a decline in their support of the brain. Aged peripheral organs interfere with pathological proteins accumulation, neuronal activity and other brain functions, ultimately promoting the dysregulation of brain homoeostasis and the occurrence of neurodegenerative diseases. FSH follicle-stimulating hormone, Aβ amyloid-β, GCs glucocorticoids, SASP senescence-associated secretory phenotype, AD Alzheimer’s disease, COVID-19 coronavirus disease 2019, NFTs neurofibrillary tangles, APP amyloid precursor protein, PTH parathyroid hormone, FGF21 fibroblast growth factor 21, Gpld1 glycosylphosphatidylinositol-specific phospholipase D1, OCN osteocalcin, LCN2 lipocalin-2, CCL11 C-C motif chemokine ligand 11, B2M β2-microglobulin, GDF11 growth differentiation factor 11, TIMP2 tissue inhibitor of metalloproteinase 2, CSF2 granulocyte‒macrophage colony stimulating factor, PD Parkinson’s disease, α-syn α-synuclein, ALS Amyotrophic lateral sclerosis, HD Huntington’s disease, FTLD Frontotemporal lobar degeneration, ANS autonomic nervous system, RAS renin–angiotensin system. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe Illustrator
Fig. 6 The impacts of the body‒brain axis ageing on neurodegenerative diseases. The brain interacts with multiple peripheral organs, and the functions and structures of peripheral organs change with age, leading to a decline in their support of the brain. Aged peripheral organs interfere with pathological proteins accumulation, neuronal activity and other brain functions, ultimately promoting the dysregulation of brain homoeostasis and the occurrence of neurodegenerative diseases. FSH follicle-stimulating hormone, Aβ amyloid-β, GCs glucocorticoids, SASP senescence-associated secretory phenotype, AD Alzheimer’s disease, COVID-19 coronavirus disease 2019, NFTs neurofibrillary tangles, APP amyloid precursor protein, PTH parathyroid hormone, FGF21 fibroblast growth factor 21, Gpld1 glycosylphosphatidylinositol-specific phospholipase D1, OCN osteocalcin, LCN2 lipocalin-2, CCL11 C-C motif chemokine ligand 11, B2M β2-microglobulin, GDF11 growth differentiation factor 11, TIMP2 tissue inhibitor of metalloproteinase 2, CSF2 granulocyte‒macrophage colony stimulating factor, PD Parkinson’s disease, α-syn α-synuclein, ALS Amyotrophic lateral sclerosis, HD Huntington’s disease, FTLD Frontotemporal lobar degeneration, ANS autonomic nervous system, RAS renin–angiotensin system. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe IllustratorCC BY · PubMed Central
Fig. 7 Holistic antiageing strategies. Antiageing strategies need to be implemented systemically at the molecular, cellular, systemic and individual levels. This holistic approach shows promise for preventing brain ageing and treating neurodegenerative diseases. C/EBPβ/AEP CCAAT-enhancer-binding protein/asparagine endopeptidase, IIS insulin/IGF-1 signalling, AMPK 5’-monophosphate-activated protein kinase, SIRT sirtuin, mTOR mammalian target of rapamycin, NAD+ nicotinamide adenine dinucleotide, Aβ amyloid-β, CR caloric restriction, MedDiet Mediterranean diet, MIND Mediterranean–DASH intervention for neurodegenerative delay, TRF time-restricted feeding. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe Illustrator
Fig. 7 Holistic antiageing strategies. Antiageing strategies need to be implemented systemically at the molecular, cellular, systemic and individual levels. This holistic approach shows promise for preventing brain ageing and treating neurodegenerative diseases. C/EBPβ/AEP CCAAT-enhancer-binding protein/asparagine endopeptidase, IIS insulin/IGF-1 signalling, AMPK 5’-monophosphate-activated protein kinase, SIRT sirtuin, mTOR mammalian target of rapamycin, NAD+ nicotinamide adenine dinucleotide, Aβ amyloid-β, CR caloric restriction, MedDiet Mediterranean diet, MIND Mediterranean–DASH intervention for neurodegenerative delay, TRF time-restricted feeding. The figure was produced utilizing the applications Easy PaintTool SAI and Adobe IllustratorCC BY · PubMed Central

Verification

Claims the paper makes

89 Valid · 5 Not valid · 242 Not checked · 87 Own results and interpretations

177 more claims · 37 with their cited sources checked

Create a free account to see all 423 claims and to verify the 329 references still open.

See all claims — free account
  • It may state two separate claims as one. 214
  • Probably not a substantial claim. 45

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

1 retracted

Show all 555 references

Research works printed but not linked: 1

  1. Gao, Y. et al. beta2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function. Cell 186, 1026–1038 e1020 (2023). · DOI · Paper page

Cited by

See all 227

Metadata

Authors
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., & Wang, Y.-J.
Affiliations
  • Army Medical University (CN)
  • Chongqing Institute for Brain and Intelligence (CN)
  • Chinese Academy of Sciences (CN)
  • Wenzhou Medical University (CN)
  • The University of Melbourne (AU)
Corresponding author
  • Masters, Colin L.
  • Wang, Yan-Jiang
Venue
Signal Transduction and Targeted Therapy
Published
2025-03-10
Volume
10
Issue
1
Pages
76-76
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4408266534
Cited by
165
References
553
Citations by year
2026: 100 · 2025: 65
FWCI
21.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
neurodegenerative diseases, Alzheimer's disease, dementia, aging, cognitive decline, disease-modifying therapy, neuroprotection, vascular comorbidities, rejuvenation
MeSH terms
Aging, Alzheimer Disease, Brain, Humans, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. https://app.cochat.ai/papers/10.1038/s41392-025-02145-7
The paper
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., & Wang, Y.-J. (2025). Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02145-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.